Drug Alert: Nuedexta - Effect of Prior Authorizations (PA) on Potential Inappropriate Part D Billing for Non-Medically Accepted Indications
Guidance for a notification of the increase in Part D utilization of Nuedexta and encouraging plan sponsors to consider the implementation of utilization management edits to ensure appropriate use of the drug.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: August 28, 2019
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.